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ABSTRACT
Objective To systemically review and critically appraise 
published studies of the association between vitamin 
D supplementation or serum vitamin D level and 
susceptibility to SARS- CoV-2 infection or COVID-19, 
including clinical course, morbidity and mortality 
outcomes.
Design Systematic review.
Data sources MEDLINE (OVID), Embase (OVID), Cochrane 
Central Register of Controlled Trials, MedRxiv and BioRxiv 
preprint databases. COVID-19 databases of the WHO, 
Cochrane, CEBM Oxford and Bern University up to 10 June 
2020.
Study selection Studies that assessed vitamin D 
supplementation and/or low serum vitamin D in patients 
acutely ill with, or at risk of, severe betacoronavirus 
infection (SARS- CoV, MERS- CoV, SARS- CoV-2).
Data extraction Two authors independently extracted 
data using a predefined data extraction form and assessed 
risk of bias using the Downs and Black Quality Assessment 
Checklist.
Results Searches elicited 449 papers, 59 studies were 
eligible full- text assessment and 4 met the eligibility 
criteria of this review. The four studies were narratively 
synthesised and included (1) a cross- sectional study 
(n=107) suggesting an inverse association between 
serum vitamin D and SARS- CoV-2; (2) a retrospective 
cohort study (348 598 participants, 449 cases) in which 
univariable analysis showed that vitamin D protects 
against COVID-19; (3) an ecological country level study 
demonstrating a negative correlation between vitamin 
D and COVID-19 case numbers and mortality; and (4) 
a case–control survey (n=1486) showing cases with 
confirmed/probable COVID-19 reported lower vitamin D 
supplementation. All studies were at high/unclear risk of 
bias.
Conclusion There is no robust evidence of a negative 
association between vitamin D and COVID-19. No relevant 
randomised controlled trials were identified and there is 
no robust peer- reviewed published evidence of association 
between vitamin D levels and severity of symptoms or 
mortality due to COVID-19. Guideline producers should 
acknowledge that benefits of vitamin D supplementation in 
COVID-19 are as yet unproven despite increasing interest.
INTRODUCTION
COVID-19, a novel viral infection caused by 
SARS- CoV-2, was declared a pandemic by the 
WHO on 11 March 2020.1 Mild COVID-19 
may manifest as high temperature, a contin-
uous cough and a loss of or change in sense 
of smell or taste.2 3 However, more severe and 
critical cases can result in inflammation of the 
lungs, low oxygen levels and acute respira-
tory distress syndrome.4 Interest is mounting 
regarding the association of vitamin D supple-
mentation or level with susceptibility to 
COVID-19 due to the recognised modulating 
Strengths and limitations of this study
 ► The strengths of this systematic review include 
that it is reported in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta- 
Analyses (PRISMA) checklist.
 ► The review was conducted by two independent re-
viewers to ensure robustness of this work.
 ► We searched multiple living systematic review data-
bases to enable us to capture publications in a fast- 
moving field of research.
 ► The limitations of the study relate to the small 
amount of evidence available which was at risk of 
bias and which limits the inferences that can be 
drawn.
 ► The review was restricted to the English language; 
therefore, non- English language papers may have 
been missed.
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effects of vitamin D on the immune system and immune 
response.
Vitamin D can modulate the immune system through 
highly expressed receptors in most non- skeletal tissues.5 6 
Two of the most common analogues of vitamin D which 
are found in food and used as a dietary supplement are 
D2 (ergocalciferol) and D3 (cholecalciferol, also made by 
the skin when exposed to sunlight).7 Both D2 and D3 can 
be hydroxylated by liver enzymes CYP2R1 and CYP27A1 
to form calcidiol (25(OH)D). The active metabolite of 
vitamin D, calcitriol (1α,25(OH)2D), results from the 
action of CYP27B enzyme on calcidiol. CYP27B is found 
in several tissues including the kidney, skin, bones and 
immune system.8 9 Tumour necrosis factor-α (TNF-α) 
and interferon-γ (IFN-γ) are examples of inflammatory 
cytokines that stimulate the CYP27B enzymes of the 
immune system.10–20 Vitamin D can interact with both the 
innate and the cellular immune systems through these 
mechanisms.
Current Public Health England (PHE),21 National Insti-
tutes of Health22 and European Food Safety Authority23 
recommendations highlight the importance of vitamin 
D to population health. Vitamin D deficiency is defined 
as less than 25 nmol/L (10 ng/mL) measured in blood 
serum.21 The UK guideline recommendations suggest 
that people take a supplement of 10 μg of vitamin D per 
day during the winter months or throughout the year 
if they do not spend time outdoors or if they cover the 
majority of their skin when outside.21 Published editorials, 
journal commentaries24–29 and news media reports30–32 
suggest that individuals with low blood serum concentra-
tions of vitamin D might be at higher risk of infection 
with COVID-19, or on infection have worse outcomes 
than individuals with normal/high serum vitamin D.33
Several observational studies have reported associa-
tions between low serum vitamin D and chronic34 and 
acute conditions such as susceptibility to acute respira-
tory tract infections (RTI).35–37 Most recently, Martineau 
and colleagues conducted a systematic review and meta- 
analysis of individual participant data from randomised 
controlled trials (RCTs) to assess the overall effect of 
vitamin D supplementation on risk of acute RTI.38 They 
reported vitamin D supplementation to be safe while 
protecting against acute RTI overall (adjusted OR 0.88, 
95% CI 0.81 to 0.96; p for heterogeneity <0.001). Patients 
very deficient in vitamin D benefited the most (adjusted 
OR 0.75, 0.60 to 0.95; p for interaction=0.006).38 Critiques 
of this review have suggested that the findings should be 
interpreted as hypothesis generating only, as the results 
are heterogeneous and not sufficiently applicable to the 
general population.39 Recent rapid reviews of vitamin D 
for treatment or prevention in COVID-19 reported no 
evidence that vitamin D deficiency predisposes to COVID-
19, or that vitamin D supplementation is effective in 
prevention or treatment of COVID-19.40 41 However, data 
sources included in the rapid review were limited.42 Given 
the remaining uncertainty, it is timely to systematically 
review and critically appraise all peer- reviewed published 
evidence to assess the association of vitamin D supplemen-
tation or level with susceptibility to SARS- CoV-2 infection 




The methods were prespecified in a protocol that was 
registered with the PROSPERO International Prospec-
tive Register of Systematic Reviews (https://www. 
crd. york. ac. uk/ prospero/ display_ record. php? ID= 
CRD42020182876). Research ethics committee approval 
was not required for this study.
We undertook a systematic review to answer the 
following question: Is vitamin D supplementation or level 
associated with susceptibility to severe betacoronavirus 
infection (SARS- CoV, Middle East respiratory syndrome 
(MERS- CoV), SARS- CoV-2) including clinical course, 
morbidity and mortality outcomes?
Our review was conceptualised and written in accor-
dance with the PRISMA statement.43
Data sources and search
The search strategy was developed by the information 
specialists in collaboration with the research team and 
clinical advisors. We searched MEDLINE (OVID inter-
face), Embase (OVID interface), Cochrane Central 
Register of Controlled Trials, MedRxiv and BioRxiv 
preprint databases on 6–8 May 2020. We searched the 
global research on COVID-19 developed by the WHO,44 
CEBM Oxford45 and the living systematic review devel-
oped by Bern University46 on 10 May 2020. We updated 
the database searches on 10 June 2020 to capture articles 
which may have been published since the initial search 
was conducted.
We searched additional resources including relevant 
systematic reviews (in MEDLINE (OVID interface), 
Embase (OVID interface) and Cochrane Database of 
Systematic Reviews, 19 May 2020), relevant references 
and contacted experts for additional evidence. Our full 
search record is included in the online supplemental file 
1.
Study eligibility
We developed predefined study eligibility criteria aligned 
to the research question (box 1). We imposed a date 
restriction of January 2002 to capture all published 
articles since SARS- CoV was first discovered in Asia in 
February 2003.47 We limited to English language only.
Article selection
Following the article search, we systematically identified 
and removed any duplicate citations using EndNote 
V.X9 software. Using titles and abstracts, deduplicated 
citations were screened by two independent reviewers 
(OO, MZ, AM, AG) and checked by a third (AC). All arti-
cles deemed ineligible were excluded at this stage. We 
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identified and obtained all remaining articles for full- text 
screening, which was performed independently by at least 
two reviewers against the prespecified eligibility criteria 
(box 1). Where disagreements regarding the inclusion 
of articles arose, a third reviewer (AC) was consulted to 
reach a final decision.
Data extraction
Two reviewers independently (LA- K, MZ, OO, AM) 
extracted data from eligible full- text papers using a 
prespecified data extraction form. The accuracy of all 
the data extraction was independently assessed by a third 
reviewer (AG). Where reported, we sought to extract 
data from each article relevant to the research question, 
including details of population, intervention/exposure, 
comparator, outcomes and any detail related to the two 
prespecified subgroups: ethnicity characteristics and age 
characteristics. Disagreements between reviewers were 
resolved by discussion and agreement or via consultation 
with a third reviewer (AC).
Risk of bias
The included studies had observational study designs 
aimed at answering a specific question. Therefore, risk 
of bias of included full- text papers was assessed using the 
Downs and Black Quality Assessment Checklist.48 Two 
reviewers (AM, MZ, OO) independently assessed the risk 
of bias of the included studies and the accuracy of the 
assessment was evaluated by a third reviewer (LA- K).
Data analysis
We anticipated that identified studies would be too hetero-
geneous to facilitate pooling of study data and planned a 
narrative synthesis. Nevertheless, we intended to consider 
pooling outcomes data in a meta- analysis using a random- 
effects model if appropriate.
Patient and public involvement
Due to the rapid timeframe of this systematic review, it 
was not possible for our research team to involve patients 
or the public in the design, conduct or reporting of our 
study.
RESULTS
After searching databases, assessing the reference lists of 
17 narrative reviews27 28 33 49–62 and one additional article 
identified through consultation with clinical experts,38 we 
identified 499 citations. Following removal of duplicates 
and screening of titles and abstracts, we retrieved 59 full- 
text papers, of which 4 met the full eligibility criteria (see 
figure 1). The electronic supplement includes a list of 
reasons for excluding studies at full- text review. Seven arti-
cles closely met the eligibility criteria but were excluded 
as they were not available as peer- reviewed publications 
at the time of our narrative synthesis, details of these 
seven studies63–69 is provided in the online supplemental 
material.
The characteristics of the four included studies are 
presented in table 1. All four included studies were 
conducted in Europe and published in April or May 2020. 
One study was based on data from UK residents exclu-
sively,70 another included data on residents in 20 Euro-
pean countries, including the UK.71 The studies were 
observational design and no relevant RCT were identified 
or included in the review. All four studies were at high 
or unclear risk of bias and scored poorly across several 
domains of the Downs and Black Quality Assessment 
Checklist,48 including external validity, internal validity 
and power. A prominent issue among the included studies 
was that the authors did not perform adequate multivari-
able adjustment to correct for confounding.72–74 Ecolog-
ical bias was present in Ilie et al,71 which may result from 
spatial and temporal scale differences between country 
level mean levels of vitamin D. However, several domains 
in each risk of bias assessment were not applicable or 
not reported and, therefore, could not be scored using 
the Downs and Black Quality Assessment Checklist.48 
Detailed risk of bias scores are provided in the online 
supplemental material.
Serum vitamin D
D’Avolio et al73 used a cross- sectional design with data on 
nasopharyngeal swab PCR analysis for SARS- CoV-2 and 
a 25(OH)D measurement taken from patients between 
1 March and 14 April 2020. PCR positives (median 
age=74 years (IQR 65–81); male=70.4%) had significantly 
(p=0.004) lower serum 25(OH)D levels (median=11.1 
Box 1 Study eligibility criteria
P—Population
1. Patients acutely ill with betacoronavirus infection (SARS- CoV, MERS- 
CoV, SARS- CoV-2).
2. Or at risk of acute illness with betacoronavirus infection.
I—Intervention/exposure
1. Vitamin D supplementation.
2. Low serum vitamin D.
O—Outcomes
1. Betacoronavirus infection (to include serological evidence of infec-
tion or clinically confirmed symptomatic infection).
2. Severe betacoronavirus infection (to include patients admitted to 
hospital or admitted to intensive care); mortality due to betacoro-
navirus infection.
3. Mortality due to betacoronavirus infection.
C—Comparators
1. No vitamin D supplementation.
2. High or normal serum vitamin D.
S—Study design
Peer- reviewed publications of randomised controlled trials and 
non- randomised studies were eligible for inclusion; including, non- 
randomised controlled trials, interrupted time series analyses, con-
trolled before- and- after studies, cohort studies, ecological studies, case 
reports and case series.
Subgroups
1. Ethnicity characteristics (white British, all other white, mixed, Asian, 
black, other).
2. Age characteristics (population by 5- year age groups).
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ng/mL (IQR 8.2–21.0)) than PCR negatives (median 
age=73 years (IQR 61–82); male=48.8%; median 25(OH)
D=24.6 ng/mL (IQR 8.9–30.5)). Although gender- 
stratified and age- stratified analysis showed no signifi-
cant differences, older (>70 years) SARS- CoV-2 positive 
(n=18) participants had significantly lower median 
serum 25(OH)D levels (9.3 ng/mL (IQR 8.1–19.9)) than 
older SARS- CoV-2 negatives (n=43) (23.1 ng/mL (IQR 
8.5–31.7)) (p=0.037).
Hastie et al70 is a retrospective cohort study that used data 
from the UK Biobank,72 using data from 348 598 people 
with complete information on vitamin D and covariates; 
449 people tested positive for COVID-19. COVID-19 posi-
tives were older (median=49 years; IQR=40–58) than 
COVID-19 negatives (median=49 years; IQR=38–57) with 
p value of <0.05. Multivariable analysis showed that age 
at assessment (OR=1.02; 95% CI=1.00 to 1.03; p=0.016) 
and non- white ethnicity (black OR=4.30, 95% CI=2.92 
to 6.31, p=<0.001; South Asian OR=2.42, 95% CI=1.50 to 
3.93, p=<0.001) were associated with confirmed COVID-
19. There was no significant interaction between ethnicity 
and vitamin D deficiency (OR=0.90; 95% CI=0.66 to 1.23; 
p=0.515). Median vitamin D concentration at recruit-
ment was lower for people with subsequent confirmed 
COVID-19 (28.7 (IQR 10.0–43.8) nmol/L) than for other 
participants (32.7 (IQR 10.0–47.2) nmol/L) (p<0.01). 
Although univariable analysis suggested an association 
between vitamin D and COVID-19 (OR=0.99; 95% CI 0.99 
to 0.999; p=0.013), this association became insignificant 
(OR=1.00; 95% CI=0.998 to 1.01; p=0.208) after adjust-
ment for covariates.70
Ilie et al71 used an ecological study design reporting 
on 20 European countries as at 8 April 2020; the data 
pertain to mean levels of vitamin D, cases of COVID-19 
per million population and deaths from COVID-19 
per million population. The authors performed Pear-
son’s correlation coefficient calculations and reported a 
negative correlation between mean levels of vitamin D 
(mean 56.79 nmol/L, SD 10.61) and numbers of cases 
of COVID-19 per million population in each country 
(mean cases 1393.4, SD 1129.984, r(20) = −0.44; p=0.05). 
Additionally, a negative correlation was reported between 
mean vitamin D levels and the number of deaths caused 
by COVID-19 per million population in each country 
(mean 80.42, SD 94.61, r(20) = −0.4378; p=0.05). Sweden 
had the highest mean level of vitamin D (73.5 nmol/L) 
compared with Spain which had a mean level of 42.5 
nmol/L). The number of cases of COVID-19 per million 
population was 834 in Sweden and 3137 in Spain. Like-
wise, at the time of the study, there were 68 deaths from 
Figure 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta- Analyses) flow diagram for the selection of 
studies.
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COVID-19 per million population in Sweden and 314 in 
Spain.
Vitamin D supplementation
Fasano et al74 investigated patients in a case–control 
phone survey in Lombardy, Italy. COVID-19 diagnosis 
was confirmed using a nasopharyngeal swab or probable 
based on (1) the presence of persistent COVID-19- related 
symptoms (≥3 including fever or ≥5 without fever); 
or (2) ≥1 symptom in the presence of suggestive chest 
radiologic signs; and/or (3) living with a family member 
with a confirmed diagnosis of COVID-19. A total of 1486 
participants were included in the survey (32 confirmed 
COVID-19, 73 probable COVID-19 and 1381 unaffected). 
Confirmed/probable COVID-19 cases (mean age=70.5 
(SD=10.1); male=53%) self- reported a significantly lower 
intake of vitamin D supplementation (12.4%) compared 
with unaffected cases (22.9%; mean age=73.0 (SD=9.5), 
male=57%). The age- adjusted OR (OR 0.56 (95% CI=0.32 
to 0.99), p=0.048) suggested a protective effect of vitamin 
D intake.
Subgroup evaluation
We planned to perform subgroup analyses by age and 
ethnicity. According to Hastie et al,70 multivariable 
analysis showed that age at assessment (OR=1.02; 95% 
CI=1.00 to 1.03; p=0.016) and non- white ethnicity (black 
OR=4.30, 95% CI=2.92 to 6.31, p<0.001; South Asians 
OR=2.42, 95% CI=1.50 to 3.93, p<0.001) were associated 
with confirmed COVID-19. However, Hastie et al found 
no significant interaction between ethnicity and vitamin 
D deficiency (OR=0.90; 95% CI=0.66 to 1.23; p=0.515).
DISCUSSION
This systematic review of non- randomised studies has 
shown no robust evidence of an association between 
vitamin D and COVID-19. We identified four studies for 
inclusion in a narrative synthesis which were all at high 
or unclear risk of bias. A univariable analysis of data from 
the UK Biobank database revealed an association between 
vitamin D and COVID-19 (OR=0.99; 95% CI 0.99 to 
0.999; p=0.013). However, this association became insig-
nificant (OR=1.00; 95% CI=0.998 to 1.01; p=0.208) after 
adjustment for 13 other covariates, suggesting that the 
initial association was due to one or more confounding 
variables.70 This view is further strengthened by the 
demonstration of highly significant associations between 
age and ethnicity characteristics as predictor variables 
and COVID-19 as the outcome variable. Overall, the 
UK Biobank study showed no effect; however, it should 
be noted that the UK Biobank data included only one 
measurement of vitamin D levels taken between 10 and 
14 years prior to the outbreak of COVID-19. This is a 
significant study limitation.
Liu et al75 concluded that patients over 60 years expe-
rienced more severe manifestations and had longer 
disease courses of COVID-19 compared with patients 
below 60 years.75 And other studies have shown that older 
(rather than younger) people are more likely to die from 
COVID-19.76–79
Non- white people are known to be more susceptible 
to COVID-19 and tend to develop worse outcomes,80 
a finding that our review has further substantiated.70 
Ethnicity is a multifaceted construct that includes genetic 
makeup, sociocultural identity and behavioural patterns.81 
It has been shown to be associated with differing 
susceptibility and treatment outcomes in a number of 
diseases.82–84 Hastie et al70 did not find any interaction 
between ethnicity and vitamin D deficiency and although 
Ilie et al71 identified a relationship, the study is subject 
to ecological bias. Ilie et al71 compared vitamin D levels 
and rates of COVID-19 across 20 European countries, and 
therefore many relevant factors were not accounted for 
in the analysis. Given the findings so far from our review, 
we consider that there is paucity of data on vitamin D 
levels and morbidity and mortality from COVID-19 and 
there is no evidence from RCTs on outcomes of vitamin D 
supplementation on severity of symptoms or mortality to 
date. However, a relationship between ethnicity, vitamin 
D (serum levels or supplementation) and susceptibility to 
or severity of COVID-19 cannot yet be ruled out.
Risk of bias assessments demonstrate that all studies 
were at high or unclear risk of bias. All studies were obser-
vational designs and therefore, subject to confounding. 
The persistent calls for high- dose vitamin D supple-
mentation85 arise from speculation about presumed 
mechanisms.86 87 Our systematic review found no robust 
evidence that low levels of vitamin D are associated with 
an increased likelihood of COVID-19. More robust prog-
nostic studies could be combined in a systematic review 
where a prognostic factor research question is phrased, 
and considerations of participation, attrition, prog-
nostic factor measurement, confounding measurement 
and account, outcome measurement, and analysis and 
reporting are evaluated.
Our systematic review identified no relevant RCTs; 
nevertheless, we are aware of two ongoing RCTs inves-
tigating the effects of vitamin D on COVID-19, the 
ZnD3- CoVici study, France (NCT04351490)88 and the 
CoVitTrial, France (NCT04344041).89 Both trials have an 
estimated study completion date of July 2020. Inclusion 
of data from these studies in future systematic reviews and 
meta- analyses may enable us to potentially draw better 
stronger conclusions on this topic. Results from the 
ongoing international VITDALIZE study (NCT03188796) 
may also contribute to our understanding of the effect of 
high- dose vitamin D3 on mortality.
90
Study limitations
We performed a full systematic review of the published 
evidence available, and simultaneous independent 
screening, data extraction and risk of bias assessments. 
However, our study is limited by the small amount of 
evidence available which was, moreover, at risk of bias. 
This limits the inferences that can be drawn. Seven 
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eligible studies were excluded because they are not avail-
able as peer- reviewed publications.63–69 If published, these 
seven studies would be included in a future update of this 
review. A final limitation is that the review was restricted 
to English language only. Therefore, articles published in 
other languages may have been excluded.
Implications for practice
Our review does not provide evidence for or against addi-
tional or high- dose vitamin D supplementation specifically 
in relation to COVID-19. Treatment as standard practice 
for people who are deficient is pre- existing practice across 
Europe23 the USA22 and in the UK.21 Current guidelines 
from PHE suggest that the entire UK population should 
take vitamin D supplements to prevent vitamin D defi-
ciency in winter or with inadequate sunlight exposure to 
sun in summer.21 This review does not give evidence to 
drive a change in this current advice. Treatment recom-
mendations for patients should be updated following 
the publication of results from ongoing and new well- 
designed adequately powered randomised controlled 
trials.
CONCLUSION
This systematic review identified no robust evidence to 
enable us to assess an association between vitamin D 
supplementation or serum vitamin D level with suscep-
tibility to COVID-19 including clinical course, morbidity 
and mortality outcomes. All studies were at high or 
unclear risk of bias. Both age and ethnicity were associ-
ated with vitamin D levels even after multivariable adjust-
ment. Black and South Asian people had a much higher 
risk of confirmed COVID-19 compared with white people. 
However, there was no interaction between the associa-
tion of ethnicity and vitamin D deficiency with COVID-19. 
There were no papers reporting association of vitamin D 
with severity of symptoms or mortality due to COVID-19.
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